News & Updates

Adjuvant treatment with pembrolizumab has significantly improved overall survival (OS) in patients with clear cell renal cell carcinoma (RCC) who are at high risk of recurrence after surgery, according to an updated analysis of the KEYNOTE-564 trial presented at ASCO GU 2024.

Combination treatment with durvalumab plus FLOT (fluorouracil, leucovorin, oxaliplatin, docetaxel) leads to higher rates of pathologic complete response (pCR) in patients with resectable gastric cancer (GC) or gastroesophageal junction cancer (GEJC), with the benefit universally observed regardless of geographic location, according to the subgroup analysis of the phase III MATTERHORN study.

Prophylactic apixaban appears to effectively reduce the risk of venous thromboembolism (VTE) for patients undergoing open surgery for gynaecologic malignancies and should be considered the standard of care for VTE prophylaxis in this population, according to a retrospective study.

First-line pembrolizumab (pembro) plus chemotherapy (chemo) in patients with untreated advanced esophageal cancer demonstrates robust efficacy after 5 years, with no new safety concerns, when compared with placebo plus chemo, according to a study presented at ASCO GI 2024.

Carpal tunnel syndrome (CTS) is not uncommon in patients being treated with anticancer therapeutic agents, reports a study. Electrodiagnostic (EDX) studies and ultrasound (US) are necessary in the diagnostic assessment of these individuals.

Thoracoscopic esophagectomy (TE) has demonstrated its noninferiority to open transthoracic esophagectomy (OE) for patients with thoracic esophageal cancer in a study presented at ASCO GI 2024.

A real-world analysis of 574 Asian patients with metastatic hormone-sensitive prostate cancer (mHSPC) demonstrated a significantly longer progression-free survival (PFS) and similar overall survival (OS) with abiraterone plus androgen deprivation therapy (ADT) vs docetaxel plus ADT.